Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;18(7):383-384.
doi: 10.1038/s41582-022-00660-7.

Ventricular enlargement caused by aducanumab

Scott Ayton  1
Affiliations
Comment

Ventricular enlargement caused by aducanumab

Scott Ayton. Nat Rev Neurol. 2022 Jul.
No abstract available

PubMed Disclaimer

Comment on

  • Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
    Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A. Budd Haeberlein S, et al. J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30. J Prev Alzheimers Dis. 2022. PMID: 35542991 Clinical Trial.

References

    1. Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. https://doi.org/10.14283/jpad.2022.30 (2022). - DOI - PubMed
    1. Massie, T., Jin, K., Wang, S. J. & Hung, J. BLA761175: Aduhelm (Aducanumab) Statistical Review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761178Orig1s000S... (FDA Centre for Drug Evaluation and Research, 2021).
    1. Cavazzoni, P. BLA761178: Aduhelm (Aducanumab) Memo https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/Aducanumab_BLA76... (FDA Centre for Drug Evaluation and Research, 2021).
    1. Ayton, S. & Bush, A. I. β-amyloid: the known unknowns. Ageing Res. Rev. 65, 101212 (2021). - DOI
    1. Ayton, S. Brain volume loss due to donanemab. Eur. J. Neurol. 28, e67–e68 (2021). - DOI

MeSH terms

Substances

LinkOut - more resources